Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort

Ava Kwong · Connie H. N. Wong · Dacita T. K. Suen · Michael Co · Allison W. Kurian · Dee W. West · James M. Ford

Published online: 31 January 2012 © The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract
Background BRCA1/2 mutation prediction models (BRCAPRO, Myriad II, Couch, Shattuck-Eidens, BOADICEA) are well established in western cohorts to estimate the probability of BRCA1/2 mutations. Results are conflicting in Asian populations. Most studies did not account for gender-specific prediction. We evaluated the performance of these models in a Chinese cohort, including males, before BRCA1/2 mutation testing.

Methods The five risk models were used to calculate the probability of BRCA mutations in probands with breast and ovarian cancers; 267 were non-BRCA mutation carriers (247 females and 20 males) and 43 were BRCA mutation carriers (38 females and 5 males).

Results Mean BRCA prediction scores for all models were statistically better for carriers than noncarriers for females but not for males. BRCAPRO overestimated the numbers of female BRCA1/2 mutation carriers at thresholds ≥20% but underestimated if <20%. BRCAPRO and BOADICEA underestimated the number of male BRCA1/2 mutation carriers whilst Myriad II underestimated the number of both male and female carriers. In females, BRCAPRO showed similar discrimination, as measured by the area under the receiver operator characteristic curve (AUC) for BRCA1/2 combined mutation prediction to BOADICEA, but performed better than BOADICEA in BRCA1 mutation prediction (AUC 93% vs. 87%). BOADICEA had the best discrimination for BRCA1/2 combined mutation prediction (AUC 87%) in males.

Conclusions The variation in model performance underscores the need for research on larger Asian cohorts as prediction models, and the possible need for customizing these models for different ethnic groups and genders.

Introduction
The identification of BRCA1 and BRCA2 mutations has dramatically changed the landscape of breast cancer in the past decade. Testing of these genes has become an important part of clinical practice. Mutations in either of these genes results in increased risk of breast and ovarian...
cancer, accounting for 5% to 10% of breast cancers and 10% to 15% of ovarian cancers [1–4]. BRCA1 is mutated more frequently in families with both breast and ovarian cancer [5, 6] and more rarely in families with male breast cancer where BRCA2 is predominant [7, 8].

Genetic testing, however, is expensive and may be associated with adverse psychological effects not only to the patient but also family members [9, 10]. Family history of breast cancer is not uncommon, but BRCA mutations are relatively rare. Establishing an efficient way to identify a “high-risk group” accurately for genetic testing is important for patient care. However, the prevalence of germline BRCA mutations in these “high-risk families” is estimated at 13–19% [11, 12]. These low figures lead to the development of models (such as BOADICEA [13], BRCAPRO [14–16], Myriad [11], Couch (also known as PENN) [17], Shattuck-Eidens [18], and Manchester [19]) that can assess the pre-test probability of identifying a BRCA1 or BRCA2 mutation and enable efficient targeting of genetic testing.

Although these models were built by using data from Caucasian populations, they are being used in clinical practice to assess the risk of BRCA1/2 mutation carriage in patients of other ethnic backgrounds [20–22] and have had variable accuracy for African Americans and Hispanics in the United States in different studies [20–23]. Indeed, the chance of carrying a genetic mutation varies between different races and is most common in Ashkenazi Jewish cohorts [24]. For ethnic populations where limited genetic studies have been undertaken, variants of unknown significance detected may be benign mutation changes but some may in fact be characterized to be pathogenic when analyzed further at an RNA level [25]. Hence, evaluation of the performance of these models in different ethnic groups has been performed so that individuals who are at risk can be accurately identified and be offered intensive surveillance and preventative measures.

Although still less-tested than in Caucasian populations, increasing numbers of Asian cohorts are being clinically tested both in Asia and in western countries, such as the United States [26–30]. A few studies have evaluated these models in a mixture of different Asian or Chinese cohorts [31–33]. Most of these studies found an underprediction of BRCA2 mutations with a comparable discriminative ability as for Caucasians. Moreover, none of the studies separately analyzed the accuracy of the use of these models in prediction of mutation carriage for males [32, 34], and therefore, there is still limited reporting of gender-specific prediction.

The purpose of our study was to compare the four commonly used BRCA1/2 mutation prediction models (BOADICEA, BRCAPRO, Myriad II, Couch and Shattuck-Eidens) to determine the likelihood of finding a BRCA1, BRCA2, or combined BRCA1/2 gene mutation in patients residing in Hong Kong, who are mainly Southern China origin Chinese, and to determine if these models can perform accurately for males.

Materials and methods

Study population

Participants were recruited through the prospective database at The Hong Kong Hereditary and High Risk Breast Cancer Family Registry (www.asiabreastregistry.com), which was established in March 2007. Protocols of the study were approved by Institutional Review Board of the participating research centers. The Registry collects data from high-risk probands and families referred to the Hong Kong Hereditary and High-Risk Breast Cancer Programme for consideration of genetic testing. Female breast and ovarian cancer patients were accrued based on age of onset, family history suggestive of hereditary predisposition, bilateral breast cancer status, and male breast cancer patients and were recruited from public and private hospitals and centers covering all areas of Hong Kong. Additional details of accrual were published in a previous study [29]. An epidemiological questionnaire, pedigree information about breast, ovarian, and/or other cancers of the first-, second-, and third-degree relatives of each proband was obtained. Unknown ages and unknown year at death were assumed to be 25 years between each generation [35].

The CancerGene software program (CaGene 4.3. The University of Texas Southwestern Medical Center,Dallas, TX) was used to calculate the probability of BRCA1, BRCA2, and BRCA1/2 mutation carriage from BRCAPRO, Myriad II, and Couch and Shattuck-Eidens models. BOADICEA risk model was calculated through https://pluto.srl.cam.ac.uk/cgi-bin/bd1/v1/bd.cgi using the most updated software available. Couch and Shattuck-Eidens models were only calculated in female participants.

All calculations were performed for male and female patients separately to evaluate how accurately BRCAPRO, Myriad II, Couch and Shattuck-Eidens, and BOADICEA models predicted risks for male and female independently. Independent t tests were used to compare any difference in mean score computed by the five carrier prediction algorithms between patients with and without BRCA mutation. Pearson χ2 goodness of fit test was used to compare the number of mutations predicted by these risk models with the actual number of mutation detected.

The area under the receiver operating characteristic (ROC) curve with 95% confidence interval for each model was used to determine discrimination. ROC was evaluated to compare the ability of these models to distinguish between patients with and without a mutation and to
measure the overall performance of each model. The closer the area under the ROC curve (AUC) is to 1, the better the overall performance of the model. A model with an AUC value of 1 is one that is perfectly accurate, whereas an AUC of 0.5 indicates no discriminating ability. The reference line distinguishes subjects who carry the BRCA mutation versus those who do not by pure chance. The resulting ROC curve would fall along this diagonal line, which is referred to as the chance diagonal. The empirical estimates of the sensitivity and specificity for positive BRCA status were calculated at the conventional testing thresholds of 10 and 20 for BRCAPRO, Myriad II, and BOADICEA models.

Fisher’s exact test was used to test for significance for small sample sizes. All tests were two-sided, and p values < 0.05 were considered statistically significant difference. All statistical analyses were performed with the SPSS for Windows Release 16.0 (SPSS Inc., Chicago, IL).

Results
A total of 310 probands (285 females and 25 males) were recruited. All were of Chinese ancestry. Among them, 267 (86.1%) individuals (247 females and 20 males) were noncarriers and 43 (13.9%) individuals (38 females and 5 males) were mutation carriers. Among 285 female probands, most were breast cancer patients (98%), and 247 (86.7%), 15 (5.3%), and 23 (8.1%) were noncarriers, BRCA1, and BRCA2 carriers respectively. Among 25 male probands, 20 (80%) and 5 (20%) were noncarriers and carriers respectively. All male mutation carriers had BRCA2 mutations. Table 1 shows the characteristics of the study population.

Table 2 shows the mean and median predicted probabilities of mutation carriage for BRCA mutation carriers and noncarriers for female patients. We found that there was significant difference in mean predicted probability by all models for female BRCA carriers versus noncarriers. BRCA mutation carriers generally had higher mean scores than noncarriers. Table 3 shows that for males, none of the models showed any significant difference in mean predicted probability between BRCA carriers and BRCA noncarriers, although BRCA mutation carriers had higher model scores overall.

Observed and expected numbers of mutation carriers by predicted carrier probability using the models are shown in Tables 4, 5, and 6. BRCAPRO predictions are seen in Table 4. In females, 16 BRCA1 and 25 BRCA2 mutation carriers were predicted and 15 and 23 were observed respectively. For a total BRCA mutation prediction of 41 carriers when 38 were observed (p for goodness of fit = 0.91), this model performed the closest predicted carrier probability. In males, three, four, and three carriers were predicted using BRCAPRO, Myriad II, and BOADICEA models respectively and five were observed.

As shown in Table 5, Myriad II predicted 32 female BRCA mutation carriers compared with the 38 observed (p = 0.444). For males, four were predicted and five were observed (p = 1.000). This was the best predictive model for males.

BOADICEA (Table 6) predicted 13 BRCA1 and 19 BRCA2 (32 in total) mutation carriers compared with 15 and 23 observed (38 in total) respectively (p = 0.723). In male probands, BOADICEA predicted three BRCA2 mutation carriers compared with five observed (p = 0.702).

For female probands, BRCAPRO (Table 4) tended to underestimate the number of BRCA1 and BRCA2 carriers at carrier probabilities <20%, but overestimated those ≥20%. Myriad II (Table 5) underestimated the number of BRCA1/2 mutation carriers for all carrier probabilities. BOADICEA (Table 6) underestimated the number of BRCA1 and BRCA2 carriers for carrier probabilities <40%, but overestimated those ≥40%. All models underestimated the expected number of males.

For BRCA1/2 prediction in females (Fig. 1a), the AUC was 0.79 using BRCAPRO, 0.72 using Myriad II, and 0.8 using BOADICEA. BRCAPRO had greatest AUC in BRCA1 specific (0.93) prediction compared with other models, and the same BRCA2 specific (0.73) prediction in females as BOADICEA. Conversely, the AUC was 0.8 using BOADICEA for BRCA1/2 mutation prediction in females and 0.87 in males (Fig. 1b); both were the highest scores compared with other models. Overall, BOADICEA had the highest discriminating power in females and males. Figures 1c and d show ROC curves for different models, comparing female BRCA1 carriers and noncarriers and BRCA2 carriers and noncarriers respectively. Figure 1e illustrates ROC curves for different models comparing male BRCA2 carriers and noncarriers.

Performance of BRCAPRO, Myriad II, Couch and Shattuck-Eidens, and BOADICEA models at conventional thresholds of 10% and 20% is shown in Table 7. In females, the highest sensitivity at both 10% and 20% cutoffs was achieved by BRCAPRO for BRCA1/2 mutations combined (73.7 and 57.9), BRCA1 mutations (86.7 and 66.7), and BRCA2 mutations (43.5 and 34.8), but its specificity was slightly lower than BOADICEA.

In males, BOADICEA had similar sensitivity compared with BRCAPRO at both 10% and 20% cutoffs (60 and 40) in BRCA1/2 combined and BRCA2 (60 and 40) but a higher specificity for BRCA1/2 combined (80 and 100 vs. 750 and 95) and BRCA2 specificity (85 and 100 vs. 75 and 95). Myriad II generally had a lower sensitivity and specificity at both 10% and 20% cutoffs except for a slightly high specificity at 20% in BRCA1/2 combined in females.
Couch and Shattuck-Eidens model had inferior sensitivities and specificities overall in our cohort.

**Discussion**

Hong Kong, being the southern part of China, is a unique place to study hereditary breast cancers in Chinese with $>80\%$ of the study population originating from southern China $[29, 36]$. Moreover, the one-child policy in Mainland China is not practiced in Hong Kong, enabling larger family structures for analysis, which is relevant because limited familial history has been reported to result in underestimation of mutation carriers by various prediction models $[33, 37]$. In 2008, more than 2,600 new breast cancer cases were diagnosed (Hong Kong Cancer Registry) and it ranked the third most common cancer after lung and colorectal malignancies and the most common cancer in

### Table 1 Personal and family history of the probands ($N = 310$)

|                      | BRCA                          |
|----------------------|-------------------------------|
|                      | Negative                      | Positive                     | All                          |
|                      | $n$ Col %                     | $n$ Col %                    | $n$ Col %                    |
| **Female ($n = 285$)** |                               |                             |                             |
| Personal history of breast cancer |                   |                               |                             |
| No                   | 3 1.2                         | 2 5.3                        | 5 1.8                       |
| Yes                  | 244 98.8                      | 36 94.7                      | 280 98.2                    |
| Personal history of ovarian cancer |                   |                               |                             |
| No                   | 242 98.0                      | 31 81.6                      | 273 95.8                    |
| Yes                  | 5 2.0                         | 7 18.4                       | 12 4.2                      |
| Personal history of breast and ovarian cancer |                   |                               |                             |
| No                   | 245 99.2                      | 33 86.8                      | 278 97.5                    |
| Yes                  | 2 0.8                         | 5 13.2                       | 7 2.5                       |
| Family history of breast cancer |                   |                               |                             |
| No                   | 4 1.6                         | 1 2.6                        | 5 1.8                       |
| Yes                  | 243 98.4                      | 37 97.4                      | 280 98.2                    |
| No. of family members with breast cancer (among those with family history with breast cancer) |   |   |   |
| $<3$                 | 223 91.8                      | 21 56.8                      | 244 87.1                    |
| $\geq3$              | 20 8.2                        | 16 43.2                      | 36 12.9                     |
| Family history of ovarian cancer |                   |                               |                             |
| No                   | 221 89.5                      | 25 65.8                      | 246 86.3                    |
| Yes                  | 26 10.5                       | 13 34.2                      | 39 13.7                     |
| Family history of breast and ovarian cancer |                   |                               |                             |
| No                   | 221 89.5                      | 26 68.4                      | 247 86.7                    |
| Yes                  | 26 10.5                       | 12 31.6                      | 38 13.3                     |
| **Male ($n = 25$)**   |                               |                             |                             |
| Personal history of breast cancer |                   |                               |                             |
| No                   | 0 0                           | 0 0                          | 0 0                         |
| Yes                  | 20 100                        | 5 100                        | 25 100                      |
| Family history of breast cancer |                   |                               |                             |
| No                   | 0 0                           | 0 0                          | 0 0                         |
| Yes                  | 20 100                        | 5 100                        | 25 100                      |
| No. of family members with breast cancer (among those with family history with breast cancer) |   |   |   |
| $<3$                 | 20 100                        | 4 80                         | 24 96                       |
| $\geq3$              | 0 0                           | 1 20                         | 1 4                         |
| Family history of ovarian cancer |                   |                               |                             |
| No                   | 20 100                        | 5 100                        | 25 100                      |
| Yes                  | 0 0                           | 0 0                          | 0 0                         |
Table 2 Difference in scoring systems between BRCA-positive and BRCA-negative using two independent $t$ statistics: females

| Age diagnosed with breast cancer (year)          | Mean | Median | Range     | $t$  | $p$ value | 95% CI      |
|-------------------------------------------------|------|--------|-----------|------|-----------|-------------|
| Noncarriers                                     | 44   | 44     | 18–82     | 1.48 | 0.14      | (−0.92, 6.51) |
| Carriers                                        | 41.5 | 39     | 26–68     |      |           |             |
| All                                              | 44   | 43.5   | 18–82     |      |           |             |
| Among carriers with breast cancer               |      |        |           |      |           |             |
| BRCA1                                           | 38   | 36     | 26–68     | −1.75| 0.089     | (−12.35, 0.92) |
| BRCA2                                           | 44   | 41     | 28–63     |      |           |             |
| Age diagnosed with ovarian cancer (year)         |      |        |           |      |           |             |
| Noncarriers                                     | 34   | 31     | 19–50     | −2.38| 0.039     | (−30.23, −0.97) |
| Carriers                                        | 50   | 49     | 38–64     |      |           |             |
| All                                              | 43.5 | 47.5   | 19–64     |      |           |             |
| Among carriers with ovarian cancer              |      |        |           |      |           |             |
| BRCA1                                           | 50   | 48     | 38–64     |      |           |             |
| BRCA2                                           | 49   | 49     | 49        |      |           |             |
| BRCA 1                                          |      |        |           |      |           |             |
| Couch                                           |      |        |           |      |           |             |
| BRCA negative                                   | 10.55| 7.7    | 0–77      | −3.04| 0.004     | (−19.58, −3.95) |
| BRCA positive                                   | 22.32| 11.7   | 0–92.4    |      |           |             |
| All                                             | 12.12| 7.7    | 0–92.4    |      |           |             |
| Shattuck-Eidens                                 |      |        |           |      |           |             |
| BRCA negative                                   | 7.11 | 4.2    | 0–74.8    | −3.04| 0.004     | (−16.71, −3.36) |
| BRCA positive                                   | 17.14| 8.05   | 1.2–85.9  |      |           |             |
| All                                             | 8.44 | 4.6    | 0–85.9    |      |           |             |
| BRCAPRO                                         |      |        |           |      |           |             |
| BRCA negative                                   | 5.65 | 0.5    | 0–93.8    | −4   | <0.001    | (−33.41, −10.96) |
| BRCA positive                                   | 27.84| 9.7    | 0–98.8    |      |           |             |
| All                                             | 8.61 | 0.8    | 0–98.8    |      |           |             |
| BOADICEA                                        |      |        |           |      |           |             |
| BRCA negative                                   | 4.37 | 1.17   | 0.03–90.07| −3.67| <0.001    | (−25.07, −7.26) |
| BRCA positive                                   | 20.53| 7.75   | 0.24–99.41|      |           |             |
| All                                             | 6.52 | 1.41   | 0.03–99.41|      |           |             |
| BRCA 2                                          |      |        |           |      |           |             |
| BRCAPRO                                         |      |        |           |      |           |             |
| BRCA negative                                   | 4.55 | 1.2    | 0–61.4    | −3.12| 0.003     | (−18.32, −3.91) |
| BRCA positive                                   | 15.67| 6.65   | 0–81.6    |      |           |             |
| All                                             | 6.04 | 1.6    | 0–81.6    |      |           |             |
| BOADICEA                                        |      |        |           |      |           |             |
| BRCA negative                                   | 3.62 | 1.72   | 0.07–39.1 | −3.38| 0.002     | (−11.71, −2.95) |
| BRCA positive                                   | 10.95| 6.5    | 0.04–59.98|      |           |             |
| All                                             | 4.59 | 1.82   | 0.04–59.98|      |           |             |
| Any BRCA                                        |      |        |           |      |           |             |
| Myriad II                                       |      |        |           |      |           |             |
| BRCA negative                                   | 9.75 | 6.8    | 2.8–53.9  | −3.66| 0.001     | (−16.58, −4.79) |
| BRCA positive                                   | 20.43| 15.8   | 2.9–79    |      |           |             |
| All                                             | 11.17| 6.8    | 2.8–79    |      |           |             |
| BRCAPRO                                         |      |        |           |      |           |             |
| BRCA negative                                   | 10.19| 2.5    | 0–99.2    | −5.54| <0.001    | (−45.4, −21.12) |
Table 2 continued

|                | Mean   | Median | Range  | t     | p value  | 95% CI          |
|----------------|--------|--------|--------|-------|----------|-----------------|
| BRCA positive  | 43.45  | 42.35  | 0–100  |       |          |                 |
| All            | 14.62  | 3.2    | 0–100  |       |          |                 |
| BOADICEA       |        |        |        |       |          |                 |
| BRCA negative  | 7.98   | 2.99   | 0.1–93.85 | -4.34 | <0.001*  | (-34.45, -12.53)|
| BRCA positive  | 31.48  | 14.79  | 1.07–99.84 |  |          |                 |
| All            | 11.12  | 3.4    | 0.1–99.84 |  |          |                 |

* There were five probands with ovarian cancer only, the number of patients with breast cancer is 280 (285-5)

b There were 12 probands in total with ovarian cancer (hence 7 with breast and ovarian cancers): 5 (41.7%) of them were noncarriers, 6 (50%) were BRCA1, and 1 (8.3%) was BRCA2

# p < 0.1 (marginal significance); * p < 0.05

Table 3 Difference in scoring systems between BRCA-positive and BRCA-negative using two independent t statistics: males

|                | Mean   | Median | Range  | t     | p value  | 95% CI          |
|----------------|--------|--------|--------|-------|----------|-----------------|
|    Male (n = 25)                                      |        |        |        |       |          |                 |
| Age diagnosed with breast cancer (year)               |        |        |        |       |          |                 |
| Noncarriers                                           | 43.45  | 42.35  | 0–100  |       |          |                 |
| Carriers (all BRCA2)                                  | 14.62  | 3.2    | 0–100  |       |          |                 |
| All                                                    | 11.12  | 3.4    | 0–100  |       |          |                 |
|    BRCA 1                                             |        |        |        |       |          |                 |
|    BRCAPRO                                           |        |        |        |       |          |                 |
| BRCA negative                                        | 30.78  | 14.1   | 7.8–96.6 | -1.37 | 0.241    | (-69.88, 23.47) |
| BRCA positive                                        | 12.22  | 7.8    | 0–96.6 |       |          |                 |
|    BOADICEA                                           |        |        |        |       |          |                 |
| BRCA negative                                        | 32.43  | 15.5   | 8.61–95.84 | -1.55 | 0.195    | (-71.44, 20.05) |
| BRCA positive                                        | 11.87  | 8.05   | 0.03–95.84 |  |          |                 |
|    Any BRCA                                           |        |        |        |       |          |                 |
|    Myriad II                                          |        |        |        |       |          |                 |
| BRCA negative                                        | 20.42  | 12.8   | 12.8–41.9 |  |          |                 |
| BRCA positive                                        | 14.28  | 12.8   | 2.8–41.9 |       |          |                 |
|    BRCAPRO                                           |        |        |        |       |          |                 |
| BRCA negative                                        | 8.04   | 5.75   | 0–30.8 |       |          | (-69.99, 23.82) |
| BRCA positive                                        | 31.12  | 14.1   | 7.8–97.2 |  |          |                 |
|    BOADICEA                                           |        |        |        |       |          |                 |
| BRCA negative                                        | 7.17   | 7.58   | 0.04–16.64 | -1.56 | 0.193    | (-71.67, 19.93) |
females. An improved understanding of hereditary breast cancer and more accurate selection of patients for genetic testing will have important implications for economic health policies.

A previous study performed by our group found 12.8% of clinically high-risk Chinese probands with breast and/or ovarian cancers carried a deleterious BRCA mutation, of which 60.7% were BRCA2 mutations [29]. This is a higher percentage of BRCA2 mutations compared with that of most Caucasian cohorts where studies have found that the prevalence of BRCA1 mutations ranges from 6.9% to 8.3% in European and American Caucasians compared with BRCA2 mutation prevalence of 5.2% to 5.9% [38–40], although consistent with other findings in Asian countries and a study performed by our group in Asian Americans [33, 41–43]. Mutations tend to be population-specific so different ethnic cohorts are likely to have a different spectrum of mutations and also different founder mutations [20, 44, 45]. In fact in a previous study, we reported a BRCA2 founder mutation in our cohort, which has accounted for the larger proportions of BRCA2 mutation carriers in our locality [36]. All of these differences are likely to result in inaccuracies in the use of existing prediction models, which have been designed based on Caucasian cohorts.

Asians comprise 57% of the world’s population and Chinese represent the largest group in the Asia continent [46], many of whom reside in western countries, such as the United States, where 4.2% of the population are Asian Americans. Therefore, Asian-specific studies and the accuracy of risk prediction models for use in this group would be of clinical relevance worldwide.

Our study indicated that BOADICEA is most accurate in predicting the numbers of BRCA1/2 mutation carriers combined compared with the other models with an AUC of 0.8 in females. It also had the closest predicted carrier probability for both male and female cohorts. Both BOADICEA and BRCPAPRO models predicted the BRCA1 mutation carriage more accurately compared with the BRCA2 mutation carriage, although BRCA1 mutation carriage was better predicted by BRCPAPRO: AUC was 0.87 (BOADICEA) and 0.93 (BRCPAPRO), respectively.

### Table 3 continued

| Carrier prob (%) | Observed | Expected | p value |
|------------------|----------|----------|---------|
| Carried prob (%) | No. AC prob | No mutation BRCA1 | BRCA2 | No mutation BRCA1 | BRCA2 | p value |
| Mean | Median | Range | t | 95% CI |
|------|-------|-------|----|-------|
| BRCA positive | 33.03 | 16.3 | 9.02–96.51 | 0.702 |
| All | 12.33 | 8.64 | 0.04–96.51 | 0.702 |

### Table 4 Observed and expected number of mutation by predicted carrier probability under BRCPAPRO: females and males

| Carrier prob (%) | Observed | Expected | p value |
|------------------|----------|----------|---------|
| No. | AC prob | No mutation BRCA1 | BRCA2 | No mutation BRCA1 | BRCA2 | p value |
|------|-------|-------|-------|-------|-------|---------|
| Female | | | | | | |
| <5 | 169 | 1.6 | 161 | 95.3 | 1 | 0.6 | 7 | 4.1 | 166.3 | 0.3 | 2.4 | 0.259 |
| 5 to <10 | 38 | 7.1 | 36 | 94.7 | 0 | 0 | 2 | 5.3 | 35.3 | 0.0 | 2.7 | 0.743 |
| 10 to <20 | 21 | 14.2 | 15 | 71.4 | 2 | 9.5 | 4 | 19 | 18 | 1 | 2 | 0.549 |
| 20 to <40 | 17 | 28.5 | 15 | 88.2 | 1 | 5.9 | 1 | 5.9 | 12.2 | 2.4 | 2.4 | 0.511 |
| ≥40 | 40 | 70.9 | 20 | 50 | 1 | 27.5 | 9 | 22.5 | 11.6 | 15.6 | 12.8 | 0.162 |
| Total | 285 | 14.6 | 247 | 86.7 | 15 | 5.3 | 23 | 8.1 | 243.4 | 16.4 | 25.2 | 0.91 |
| Male | | | | | | |
| <5 | 7 | 2.3 | 7 | 100 | 0 | 0 | 0 | 0 | 6.8 | 0 | 0.2 | 0.475 |
| 5 to <10 | 9 | 6.9 | 7 | 77.8 | 0 | 0 | 2 | 22.2 | 8.4 | 0 | 0.6 | 1.000 |
| 10 to <20 | 6 | 13.6 | 5 | 83.3 | 0 | 0 | 1 | 16.7 | 5.2 | 0 | 0.8 | 1.000 |
| 20 to <40 | 2 | 29.6 | 1 | 50 | 0 | 0 | 1 | 50 | 1.4 | 0 | 0.6 | 1.000 |
| ≥40 | 1 | 97.2 | 0 | 0 | 0 | 1 | 100 | 0 | 0 | 1 | 1.000 |
| Total | 25 | 12.7 | 20 | 80 | 0 | 0 | 5 | 20 | 21.8 | 0 | 3.2 | 0.702 |

Carrier Prob (%) range of carrier probability for each proband data; No. number of probands in the corresponding range; AC Prob (%) average carrier probability in the corresponding range

† Pearson χ² goodness of fit test
Overall for the BRCAPRO and BOADICEA models, the AUC of 0.8 for BRCA1/2 mutations combined were higher than previous reports by Rao et al. (0.725) [34], Euhus et al. (0.712) [47], Marroni et al. (0.757) [48], Antoniou et al. (0.76) [49], and Kurian et al. (0.71 for Asians, 0.77 for whites) [33]. Possible reasons for predictions being...

Table 5  Observed and expected number of mutation by predicted carrier probability under Myriad II: females and males

| Carrier prob (%) | No. | AC Prob | Observed | | | Expected | | | p value† |
|------------------|-----|---------|----------|----------|----------|----------|----------|----------|
|                  | n   | %       | No mutation | Any BRCA | No mutation | Any BRCA |
| Female           |     |         | n | row% | n | row% | n | N |
| <5               | 46  | 2.9     | 45 | 97.8 | 1 | 2.2 | 44.7 | 1.3 | 1.000 |
| 5 to <10         | 161 | 6.7     | 148 | 91.9 | 13 | 8.1 | 150.2 | 10.8 | 0.671 |
| 10 to <20        | 45  | 15.8    | 35 | 77.8 | 10 | 22.2 | 37.9 | 7.1 | 0.419 |
| 20 to <40        | 27  | 33.8    | 16 | 59.3 | 11 | 40.7 | 17.9 | 9.1 | 0.573 |
| ≥40              | 6   | 58.4    | 3  | 50.0 | 3  | 50.0 | 2.5  | 3.5 | 1.000 |
| Total            | 285 | 11.2    | 247 | 86.7 | 38 | 13.3 | 253.1 | 31.9 | 0.444 |
| Male             |     |         |     |       |     |       |     |       |         |
| <5               | 1   | 2.8     | 1  | 100  | 0  | 0    | 0.97 | 0.03 | 1.000 |
| 5 to <10         | 0   | 0.0     | 0  | 0    | 0  | 0    | 0    | 0    | –      |
| 10 to <20        | 21  | 12.8    | 18 | 85.7 | 3  | 14.3 | 18.3 | 2.7 | 1.000 |
| 20 to <40        | 2   | 21.8    | 1  | 50   | 1  | 50   | 1.6  | 0.4 | 1.000 |
| ≥40              | 1   | 41.9    | 0  | 0    | 1  | 100  | 0.6  | 0.4 | 1.000 |
| Total            | 25  | 14.3    | 20 | 80   | 5  | 20   | 21.4 | 3.6 | 1.000 |

Carrier Prob (%) range of carrier probability for each proband data; No. number of probands in the corresponding range; AC Prob (%) average carrier probability in the corresponding range

Table 6  Observed and expected number of mutation by predicted carrier probability under BOADICEA: females and males

| Carrier prob (%) | No. | AC Prob | Observed | | | Expected | | | p value† |
|------------------|-----|---------|----------|----------|----------|----------|----------|----------|
|                  | n   | %       | No mutation | BRCA1 | BRCA2 | No mutation | BRCA1 | BRCA2 |
| Female           |     |         | n | row% | n | row% | n | n |
| <5               | 171 | 2.1     | 163 | 95.3 | 2 | 1.2 | 6 | 3.5 | 167.4 | 0.9 | 2.7 | 0.424 |
| 5 to <10         | 35  | 6.9     | 31 | 88.6 | 1 | 2.9 | 3 | 8.6 | 32.6  | 0.6 | 1.8 | 0.809 |
| 10 to <20        | 42  | 14.0    | 32 | 76.2 | 4 | 9.5 | 6 | 14.3 | 36.1  | 2.4 | 3.5 | 0.53  |
| 20 to <40        | 14  | 27.3    | 9  | 64.3 | 2 | 14.3 | 3 | 21.4 | 10.2  | 1.5 | 2.3 | 0.898 |
| ≥40              | 23  | 69.9    | 12 | 52.2 | 6 | 26.1 | 5 | 21.7 | 6.9   | 8.8 | 7.3 | 0.326 |
| Total            | 285 | 11.1    | 247 | 86.7 | 15 | 5.3 | 23 | 8.1 | 253.4 | 12.5 | 19.2 | 0.723 |
| Male             |     |         |     |       |     |       |     |       |         |
| <5               | 6   | 1.2     | 6  | 100.0 | 0 | 0.0 | 0 | 0.0 | 5.9   | 0.0 | 0.1 | 1.000 |
| 5 to <10         | 11  | 7.9     | 9  | 81.8 | 0 | 0.0 | 2 | 18.2 | 10.1  | 0.0 | 0.9 | 1.000 |
| 10 to <20        | 6   | 13.9    | 5  | 83.3 | 0 | 0.0 | 1 | 16.7 | 5.2   | 0.0 | 0.8 | 1.000 |
| 20 to <40        | 1   | 34.2    | 0  | 0.0  | 0 | 0.0 | 1 | 100.0 | 0.7   | 0.0 | 0.3 | 1.000 |
| ≥40              | 1   | 96.5    | 0  | 0.0  | 0 | 0.0 | 1 | 100.0 | 0.04  | 0.0 | 0.97 | 1.000 |
| Total            | 25  | 12.3    | 20 | 80.0 | 0 | 0.0 | 5 | 20.0 | 21.9  | 0.0 | 3.1 | 0.702 |

Carrier Prob (%) range of carrier probability for each proband data; No. number of probands in the corresponding range; AC Prob (%) average carrier probability in the corresponding range

† Pearson χ² goodness of fit test
higher in our study may be attributed to the differences in the prevalence of mutations, differences in mutation spectrum, and penetrance. Most other studies performed in Asians comprised a mixture of different Asian ethnic groups, including Vietnamese, Koreans, Filipinos, Malays, and Indians, whereas ours study was limited to southern Chinese. Moreover, a prediction model’s accuracy is dependent of the proband’s own account of family cancer
The reporting of family history may have differed in other studies where three generations of family history may not have been elicited which may also explain the differences in the estimation of BRCA mutations using these prediction models between studies. Another possible explanation for the differences is the use of gender-specific analysis in our study. For the few males we included in our study, we found that the models did not have any different predictive probability between BRCA2 mutation carriers and noncarriers and they all underpredicted BRCA2 mutations by nearly twofold (there were no BRCA1 carriers). Risk prediction models should be used with caution in males because there is a lack of studies to assess the accuracy of the use of such models in male cohorts alone. One Caucasian study did find that BODICEA 5.0 can achieve a prediction sensitivity of 0.8 for BRCA1/2 and 0.63 for BRCA2 at 10% threshold. A larger cohort of male probands is necessary to allow further confirmation of our studies’ findings. Consistent with previous reported studies, we found that both BOADICEA and BRCAPRO models underestimated the number of mutations carriers at a lower threshold and overestimated at a higher threshold.

Recent studies have found that accuracy of risk prediction models can be improved by incorporating pathologic information into the algorithm. Our previous studies found that approximately 20–30% of women with BRCA mutation elected for prophylactic contralateral mastectomy and salpingo-oophorectomy, including unaffected family members of probands who have found themselves to be mutation carriers. Revised versions of the BRCAPRO model incorporate such information and may improve on the prediction accuracy that we report here.

The strength of this study is its representation of the broader Hong Kong population, because most cancer genetics referrals are seen at our institution through the referral to the Hong Kong Hereditary and High-Risk Breast Cancer Programme. Unlike many prior studies, complete genetic testing, including full gene sequencing and multiplex ligation-dependent probe amplifications (MLPA), was performed on all patients to minimize the chance of false negatives. Limitations include a clinic-based cohort rather than population-based setting, and a relatively small sample size especially for males, given the rarity of their disease.

We found underestimation of BRCA2 mutations in this Chinese cohort by standard mutation prediction models, despite relatively satisfactory discriminative ability; given that BRCA2 mutations are more prevalent in Asian and male cohorts, this finding has clinical significance. Further studies in larger cohorts, including Asians and males, are indicated, with the goal of developing an accurate predictive model specific to these populations and of targeting genetic testing more accurately for optimal patient care.

### Table 7

|                  | Conventional threshold (%) | Sensitivity at conventional threshold (%) | Specificity at conventional threshold (%) |
|------------------|----------------------------|------------------------------------------|------------------------------------------|
|                  |                           | BRCA carrier vs. non-carrier             | BRCA1 vs. non-BRCA1                      | BRCA2 vs. non-BRCA2                      | BRCA carrier vs. non-carrier | BRCA1 vs. non-BRCA1 | BRCA2 vs. non-BRCA2 |
| **Female model** |                            |                                          |                                          |                                          |                            |                            |                            |
| BRCAPRO          | 10                        | 73.7                                    | 86.7                                    | 43.5                                    | 79.8                        | 86.7                        | 90.1                        |
|                  | 20                        | 57.9                                    | 66.7                                    | 34.8                                    | 86.2                        | 91.5                        | 94.3                        |
| Myriad II        | 10                        | 63.2                                    | –                                       | –                                       | 78.1                        | –                           | –                           |
|                  | 20                        | 34.2                                    | –                                       | –                                       | 92.3                        | –                           | –                           |
| Couch            | 10                        | –                                       | 80                                      | –                                       | –                           | 64.8                        | –                           |
|                  | 20                        | –                                       | 46.7                                    | –                                       | –                           | 90.7                        | –                           |
| Shattuck-Eidens  | 10                        | –                                       | 66.7                                    | –                                       | –                           | 80.4                        | –                           |
|                  | 20                        | –                                       | 46.7                                    | –                                       | –                           | 93                          | –                           |
| BOADICEA         | 10                        | 68.4                                    | 60                                      | 30.4                                    | 78.9                        | 89.3                        | 90.8                        |
|                  | 20                        | 42.1                                    | 46.7                                    | 17.4                                    | 91.5                        | 94.1                        | 96.9                        |
| **Male model**   |                            |                                          |                                          |                                          |                            |                            |                            |
| BRCAPRO          | 10                        | 60                                      | –                                       | 60.0                                    | 75                          | –                           | 75                          |
|                  | 20                        | 40                                      | –                                       | 40.0                                    | 95                          | –                           | 95                          |
| Myriad II        | 10                        | 40                                      | –                                       | –                                       | 95                          | –                           | –                           |
|                  | 20                        | 20                                      | –                                       | –                                       | 100                         | –                           | –                           |
| BOADICEA         | 10                        | 60                                      | –                                       | 60                                      | 80                          | –                           | 85                          |
|                  | 20                        | 40                                      | –                                       | 40                                      | 100                         | –                           | 100                         |
Acknowledgments The authors thank Dr. Ellen Li Charitable Foundation and Kuok Foundation for their support for the work of The Hong Kong Hereditary Breast Cancer Family Registry (www.asiabreastregistry.com) and The Hong Kong Hereditary and High-Risk Breast Cancer Programme. They also thank Miss Ling Wong, Dr. Annie Chu, and Miss Elaine Tsui for their help in recruitment of patients for the study. Sincere thanks to Dr. Fian Law, Dr. L.P. Wong, Dr. Edmond S.K. Ma, and Hong Kong Sanatorium and Hospital for the support on genetic testing and the laboratory work. The authors thank doctors in other Hospital Authority-based hospitals and the private sector who have contributed in recruitment of patients for this study, including G. Au, K.L.L. Chan, M.C.M. Chan, W.C. Chan, S. Chan, C. Choi, L.S. Ho, B.Y.K. Lam, F.C.S. Leung, R. Leung, T.Y. Ng, H.Y.S. Ngan, M. Poon, J.W. Tsang, K.F. Tam, D.C.T. Wong, T.T. Wong, and M.W.L. Ying.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130
2. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333
3. Risch HA, McLaughlin JR, Cole DE et al (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694–1706
4. Pal T, Permuth-Wey J, Betts JA et al (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807–2816
5. Beristain E, Martinez-Bouzas C, Guerra I et al (2007) Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling. Breast Cancer Res Treat 106:255–262
6. Martin AM, Blackwood MA, Antin-Ozerkis D et al (2001) Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol 19:2247–2253
7. Shah P, Robbani I, Shah O (2009) Clinicopathological study of male breast carcinoma: 24 years of experience. Ann Saudi Med 29:288–293
8. Ottini L, Rizzolo P, Zanna I et al (2009) BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 116:577–586
9. Kash KM, Ortega-Verdejo K, Dabney MK et al (2000) Psychosocial aspects of cancer genetics: women at high risk for breast and ovarian cancer. Semin Surg Oncol 18:333–338
10. McInerney-Leo A, Biesecker BB, Hadley DW et al (2005) BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships. Am J Med Genet A 133A:165–169
11. Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480–1490
12. Antoniou AC, Pharoah PD, McMullan G et al (2002) A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 86:76–83
13. Antoniou AC, Durocher F, Smith P et al (2006) BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 8:R3
14. Berry DA, Parmigiani G, Sanchez J et al (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227–238
15. Berry DA, Iversen ES Jr, Gudbjartsson DF et al (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701–2712
16. Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158
17. Couch FF, DeShano ML, Blackwood MA et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409–1415
18. Shattuck-Eidens D, Oliphant A, McClure M et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278:1242–1250
19. Evans DG, Eccles DM, Rahman N et al (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation out-performs existing models including BRCAPRO. J Med Genet 41:474–480
20. Weitzel JN, Lagos V, Blazer KR et al (2005) Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 14:1666–1671
21. Nanda R, Schumm LP, Cummings S et al (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294:1925–1933
22. Vogel KJ, Atchley DP, Erlichman J et al (2007) BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25:4635–4641
23. Kurian AW, Gong GD, John EM et al (2009) Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 18:1084–1091
24. Rubinstein WS (2004) Hereditary breast cancer in Jews. Fam Cancer 3:249–257
25. Kwon A, Wong LP, Chan KY et al (2008) Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Fam Cancer 7:125–133
26. Hu Z, Li WF, Liu XY et al (2008) BRCA1/2 gene mutation in Chinese familial breast cancer patients: a multi-center report of 115 cases. Zhonghua Yi Xue Za Zhi 88:2383–2386
27. Han SH, Lee KR, Lee DG et al (2006) Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer. Clin Genet 70:496–501
28. Li WF, Hu Z, Rao NV et al (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110:99–109
29. Kwon A, Wong LP, Wong HN et al (2009) Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. Hum Genet 125:765–776
30. Ikeda N, Miyoshi Y, Yoneda K et al (2001) Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer 91:83–88
31. Thirthagiri E, Lee S, Kang P et al (2008) Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res Treat 113:467–477

32. Rao NY, Hu Z, Li WF et al (2009) Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients. Breast Cancer Res Treat 116:563–570

33. Kurian AW, Gong GD, Chun NM et al (2008) Performance of BRCA1/2 Mutation Prediction Models in Asian Americans. J Clin Oncol 26(29):4752–4758

34. Rao NY, Hu Z, Yu JM et al (2008) Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients. Breast Cancer Res Treat 116:563–570

35. Panchal SM, Ennis M, Canon S, Bordeleau LJ (2008) Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet 9:116

36. Kwong A, Wong LP, Wong HN et al (2009) A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat 117:683–686

37. Weitzel JN, Lagos VI, Cullinane CA et al (2007) Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 297:2587–2595

38. Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308

39. Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949

40. Hall MJ, Reid JE, Burbidge LA et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115:2222–2233

41. Hou MF, Tsai KB, Fan HM et al (2000) Familial breast cancer in southern Taiwan. Kaohsiung J Med Sci 16:414–421

42. Ahn SH, Son BH, Yoon KS et al (2007) BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Lett 245:90–95

43. Malone KE, Daling JR, Doody DR et al (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66:8297–8308

44. Johannesdottir G, Gudmundsson J, Berghorsson IT et al (1996) High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 56:3663–3665

45. John EM, Miron A, Gong G et al (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298:2869–2876

46. Liede A, Narod SA (2002) Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 20:413–424

47. Euhus DM, Smith KC, Robinson L et al (2002) Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCA PRO. J Natl Cancer Inst 94:844–851

48. Marroni F, Aretini P, D’Andrea E et al (2004) Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet 41:278–285

49. Antoniou AC, Hardy R, Walker L et al (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCA PRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45:425–431

50. Katki HA (2006) Effect of misreported family history on Mendelian mutation prediction models. Biometrics 62:478–487

51. Barlow-Stewart K, Yeo SS, Meiser B et al (2006) Toward cultural competence in cancer genetic counseling and genetics education: lessons learned from Chinese-Australians. Genet Med 8:24–32

52. Zanna I, Rizzolo P, Sera F et al (2010) The BRCA PRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases. Eur J Hum Genet 18:856–858

53. Huo D, Senie RT, Daly M et al (2009) Prediction of BRCA mutations using the BRCA PRO model in clinic-based African American, Hispanic, and other minority families in the United States. J Clin Oncol 27:1184–1190

54. Mavaddat N, Rebbeck TR, Lakhani SR et al (2010) Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res 12:R28

55. Kwong A, Wong CH, Shea C et al (2010) Choice of management of southern Chinese BRCA mutation carriers. World J Surg 34:1416–1426. doi:10.1007/s00268-010-0477-5

56. Katki HA (2007) Incorporating medical interventions into carrier probability estimation for genetic counseling. BMC Med Genet 8:13